icon
icon
icon
icon
Upgrade
Upgrade

News /

Articles /

CASI Pharmaceuticals 2025 Q1 Earnings Revenue Surges Despite Wider Net Loss

Daily EarningsSaturday, May 17, 2025 3:04 am ET
15min read
CASI Pharmaceuticals (CASI) announced its fiscal 2025 Q1 earnings on May 16th, 2025. The company reported a significant increase in revenue, with a rise of 83% to $6.24 million compared to the previous year's Q1. Despite this strong revenue growth, CASI's net loss widened, driven by increased legal fees. The company did not adjust its guidance but remains optimistic about strategic initiatives focusing on CID-103.

Revenue
CASI Pharmaceuticals showcased a notable increase in revenue for Q1 2025, with total earnings reaching $6.24 million. This marks an 83% rise compared to $3.41 million in Q1 2024. Product sales constituted the entire revenue figure, demonstrating the company's successful commercial strategy.

Earnings/Net Income
The company reported a net loss of $10.75 million for Q1 2025, up 12.8% from a $9.53 million loss in the same quarter last year. While losses per share narrowed slightly to $0.69 from $0.71, the increased legal expenses impacted the net income, indicating ongoing financial challenges.

Price Action
The stock price of CASI Pharmaceuticals has edged down 1.47% during the latest trading day, has edged up 2.94% during the most recent full trading week, and has edged down 2.47% month-to-date.

Post-Earnings Price Action Review
The strategy of investing in CASI Pharmaceuticals following revenue shortfalls and holding for 30 days has demonstrated a strong track record of outperforming the broader market. Investors utilizing this approach have seen a return of 20.4%, compared to the SPY's gain of 14.4% over the same period. This strategy effectively capitalizes on rebound opportunities, making it a valuable component of a diversified portfolio. The consistent success of this approach underscores its potential to harness post-earnings price fluctuations, providing investors with an advantageous edge in navigating market dynamics.

CEO Commentary
Dr. Wei-Wu He, Ph.D., Chairman and CEO, expressed confidence in CASI's strategic focus, particularly highlighting the advancement of CID-103 with the initiation of patient dosing in a Phase 1/2 study for chronic immune thrombocytopenia. He noted efforts to resolve FDA holds and emphasized the importance of recent divestitures in China, which allow the company to concentrate on core priorities and enhance value for patients and shareholders amid legal challenges.

Guidance
CASI Pharmaceuticals anticipates continued revenue growth, reporting Q1 2025 revenues of $6.24 million, reflecting an 82% increase from the prior year. While legal expenses contributed to a net loss of $10.75 million, the company remains optimistic about its strategic focus, particularly on CID-103. Further, CASI expects to leverage its remaining product rights to drive future growth, although specific quantitative targets for future quarters were not disclosed in the commentary.

Additional News
CASI Pharmaceuticals has entered into a definitive Equity and Assets Transfer Agreement with Kaixin Pharmaceuticals Inc. to sell its subsidiaries in China for $20 million. This strategic divestiture aims to sharpen CASI's focus on its core priorities, particularly the advancement of CID-103 for organ transplant rejection and autoimmune diseases. The transaction includes the transfer of rights related to BI-1206, CID-103, and Thiotepa in specified regions. Additionally, CASI appointed a new CFO on May 14, 2025, as part of its efforts to strengthen financial leadership amidst ongoing legal challenges and market dynamics. The company is also navigating potential Nasdaq delisting concerns due to fluctuating market value, adding complexity to its operational landscape.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.